BIOLINERX     Print Page  Close Window

SEC filings
BIOLINERX LTD. filed this Form 424B5 on 07/26/2017
Entire Document

The SEC allows us to incorporate by reference our publicly filed reports into this prospectus supplement, which means that information included in those reports is considered part of this prospectus supplement.  Information that we file with the SEC after the date of this prospectus supplement will automatically update and supersede the information contained in this prospectus supplement.  We incorporate by reference our Annual Report on Form 20-F for the year ended December 31, 2016, filed with the SEC on March 23, 2017, and any future filings made with the SEC under sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act).
We will furnish without charge to you, on written or oral request, a copy of any or all of the above documents, other than exhibits to such documents which are not specifically incorporated by reference therein.  You should direct any requests for documents to:
BioLineRx Ltd.
Modi’in Technology Park
2 HaMa’ayan Street
Modi’in 7177871, Israel
Attention: Corporate Secretary
Tel.: +972-8-642-9100
The information relating to us contained in this prospectus supplement is not comprehensive and should be read together with the information contained in the incorporated documents.  Descriptions contained in the incorporated documents as to the contents of any contract or other document may not contain all of the information which is of interest to you.  You should refer to the copy of such contract or other document filed as an exhibit to our filings.
We have filed with the SEC a registration statement on Form F-3 under the Securities Act of 1933, as amended (the Securities Act), relating to this offering of securities. This prospectus supplement does not contain all of the information contained in the registration statement.  The rules and regulations of the SEC allow us to omit certain information from this prospectus supplement that is included in the registration statement.  Statements made in this prospectus supplement concerning the contents of any contract, agreement or other document are summaries of all material information about the documents summarized, but are not complete descriptions of all terms of these documents.  If we filed any of these documents as an exhibit to the registration statement, you may read the document itself for a complete description of its terms.
In addition, we file reports with, and furnish information to, the SEC.  You may read and copy the registration statement and any other documents we have filed at the SEC, including any exhibits and schedules, at the SECs public reference room at 100 F Street N.E., Washington, D.C. 20549.  You may call the SEC at 1-800-SEC-0330 for further information on this public reference room.  As a foreign private issuer, all documents which were filed after September 24, 2010 on the SECs EDGAR system are available for retrieval on the SECs website at  These SEC filings are also available to the public on the Israel Securities Authoritys Magna website at and from commercial document retrieval services.  We also generally make available on our own web site ( our quarterly and year-end financial statements as well as other information.
In addition, since our Ordinary Shares are traded on the TASE, in the past we filed Hebrew language periodic and immediate reports with, and furnished information to, the TASE and the Israel Securities Authority, or the ISA, as required under Chapter Six of the Israel Securities Law, 1968.  On August 31, 2011, our shareholders approved a transition solely to U.S. reporting standards after listing the ADSs on the Nasdaq Capital Market, in accordance with an applicable exemption under the Israel Securities Law.  Copies of our SEC filings and submissions are now submitted to the ISA and the TASE.  Such copies can be retrieved electronically through the MAGNA distribution site of the ISA ( and the TASE website (
We maintain a corporate website at  Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus supplement.  We have included our website address in this prospectus supplement solely as an inactive textual reference.
S - 12